GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...

LILLY GLP-1 SHORTAGE ENDS — The FDA declared this week that tirzepatide, the GLP-1 used in Eli Lilly’s blockbuster diabetes ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...

In a consultation the UK's drugs watchdog has now proposed the NHS expands its use for weight loss for those who are severely ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

The US Food and Drug Administration confirmed Thursday that Eli Lilly (LLY) has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the ...

Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The chip maker invested about $100 million in OpenAI's latest funding round, The Wall Street Journal reports. The CEO will need to convince investors that the company is still more than an auto maker.